Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/6000
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Haddad, Albert | en_US |
dc.contributor.author | Jabbour, Michel | en_US |
dc.contributor.author | Bulbul, Muhammad | en_US |
dc.date.accessioned | 2022-08-11T10:07:36Z | - |
dc.date.available | 2022-08-11T10:07:36Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 2090-598X | - |
dc.identifier.uri | https://scholarhub.balamand.edu.lb/handle/uob/6000 | - |
dc.description.abstract | Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor. | en_US |
dc.language.iso | eng | en_US |
dc.subject | 5ARI, 5α-reductase inhibitor | en_US |
dc.subject | AE, adverse event | en_US |
dc.subject | Benign prostatic hyperplasia | en_US |
dc.subject | ED, erectile dysfunction | en_US |
dc.subject | EF, erectile function (domain) | en_US |
dc.subject | Erectile dysfunction | en_US |
dc.subject | IIEF, International Index of Erectile Function | en_US |
dc.subject | LUTS | en_US |
dc.subject | NO, nitric oxide | en_US |
dc.subject | PDE5 inhibitor | en_US |
dc.subject | PDE5, phosphodiesterase type 5 | en_US |
dc.subject | QoL, quality of life | en_US |
dc.subject | ROCK, Rho-associated protein kinase | en_US |
dc.subject | RhoA, Ras homologue gene family member A | en_US |
dc.subject | cGMP, cyclic guanosine monophosphate | en_US |
dc.title | Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.1016/j.aju.2015.06.004 | - |
dc.identifier.pmid | 26413339 | - |
dc.identifier.scopus | 2-s2.0-84940461195 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/84940461195 | - |
dc.description.volume | 13 | en_US |
dc.description.issue | 3 | en_US |
dc.description.startpage | 155 | en_US |
dc.description.endpage | 161 | en_US |
dc.date.catalogued | 2022-08-11 | - |
dc.description.status | Published | en_US |
dc.identifier.openURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4563010/ | en_US |
dc.relation.ispartoftext | Arab Journal of Urology | en_US |
dc.description.campus | SGH campus | en_US |
Appears in Collections: | Faculty of Medicine |
SCOPUSTM
Citations
10
checked on Nov 23, 2024
Record view(s)
45
checked on Nov 24, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.